文献速递脑血管病

秋水仙碱预防急性脑出血后血管事件:安慰剂对照试验

Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage: A Placebo-Controlled Trial.
PubMed 文献 · Stroke · 2026-08-06

这项在加拿大11个中心开展的双盲、安慰剂对照预试验,纳入急性脑出血后48小时内、有动脉粥样硬化影像学证据或危险因素的成人,随机接受口服秋水仙碱0.5 mg每日或安慰剂,主要可行性结局为每年每中心招募率。结果显示平均招募率8.9例/中心/年,6个月保留率92%,12个月服药依从性97%,中位随访364天未发现预设探索性疗效或安全性终点差异,结论是在急性脑出血后测试低剂量秋水仙碱可行,未来试验需考虑早期永久停药率较高。

要点

  • 急性脑出血后48小时内随机给予秋水仙碱0.5 mg每日可行,招募率8.9例/中心/年。
  • 6个月保留率92%,12个月服药依从性97%,两组合计早期永久停药率27%。
  • 中位随访364天,预设探索性疗效与安全性终点两组未见差异。

核心结论

  • 在急性脑出血后测试低剂量秋水仙碱是可行的,未来随机临床试验应考虑到该人群早期永久停药率较高。

研究设计与样本

  • 双盲、安慰剂对照、预试验随机临床试验,在加拿大11个中心开展。
  • 招募脑出血发病48小时内、有血管神经影像学证据或动脉粥样硬化危险因素的成人。
  • 52例分配至秋水仙碱0.5 mg每日,48例分配至安慰剂每日,随访至共同研究终止日期。
  • 主要可行性结局为招募率(参与者/中心/年),次要可行性结局包括6个月保留率和12个月服药依从性。

主要发现

  • 参与者平均年龄68岁,60%为男性,脑出血发病至随机化平均时间35小时。
  • 平均招募率为8.9例/中心/年。
  • 6个月保留率为92%(秋水仙碱91% vs 安慰剂93%)。
  • 随机化后秋水仙碱组14例(27%)和安慰剂组13例(27%)永久停用研究药物。
  • 排除死亡或永久停用研究干预的参与者后,12个月服药依从性为97%,秋水仙碱组与安慰剂组分别为100%和93%。

临床怎么用

  • 该预试验结果为在急性脑出血人群开展低剂量秋水仙碱的后续随机临床试验提供了可行性依据。
  • 设计后续试验时应考虑该人群早期永久停用研究药物比例较高的问题。

局限性

  • 原文为预试验,主要目的为评估可行性,未报告预设探索性疗效或安全性终点的组间差异。
  • 原文未报告样本量计算、把握度、具体探索性终点定义及不良事件明细。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a need for novel treatments that lower the risk of major adverse cardiovascular events and secondary inflammatory brain injury after an intracerebral hemorrhage (ICH). METHODS: We performed a double-blind, placebo-controlled, pilot randomized clinical trial at 11 centers across Canada to determine the feasibility of testing colchicine after an acute ICH. We recruited adults presenting within 48 hours of ICH onset with vascular neuroimaging evidence or risk factors for atherosclerosis. Participants were randomized to oral colchicine 0.5 mg daily or placebo and followed to a common study termination date. The primary feasibility outcome was the recruitment rate (participants/center per year). Secondary feasibility outcomes included retention of participants at 6 months and medication adherence at 12 months. This trial is registered (URL: https://www.clinicaltrials.gov; Unique identifier: NCT05159219). RESULTS: Between August 2022 and March 2024, 52 participants were allocated to colchicine 0.5 mg daily and 48 participants to placebo daily. Participants were, on average, 68 years old, and 60% were male. The mean time from ICH onset to randomization was 35 hours. The average recruitment rate was 8.9 participants/site per year. Retention at 6 months was 92% (colchicine 91% versus placebo 93%). Following randomization, 14 participants (27%) in the colchicine group and 13 participants (27%) in the placebo group permanently discontinued the study drug. Excluding participants who died or permanently discontinued the study intervention, 12-month medication adherence was 97%, with similar rates between the colchicine and placebo groups (100% versus 93%). We detected no difference in predefined exploratory efficacy or safety end points between the 2 groups over the median follow-up time of 364 days. CONCLUSIONS: It is feasible to test low-dose colchicine after an acute ICH. Future randomized clinical trials should account for the high rates of early permanent study drug discontinuation in this patient population. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05159219.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Katsanos AH, Ng KKH, Field TS, et al. Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage: A Placebo-Controlled Trial. Stroke. 2026. PMID: 42558067. doi:10.1161/STROKEAHA.126.055934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。